LncRNA-SNHG7 Enhances Chemotherapy Resistance and Cell Viability of Breast Cancer Cells by Regulating MiR-186

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Oct 29

PMID 33116871

Citations 11

Authors

Hui Zhang

Xiao-Yu Zhang

Xiao-Ning Kang

Li-Jun Jin

Zun-Yi Wang

Affiliations

Soon will be listed here.

Abstract

Background: Clinical tolerance to trastuzumab greatly affects the therapeutic effect in breast cancer (BC). Long-chain non-coding RNA (lncRNA) plays an important role in the development of trastuzumab resistance, in which SNHG7 can promote the epithelial mesenchymal transformation (EMT) of breast cancer cells into, while EMT is related to trastuzumab resistance of breast cancer cells.

Objective: To investigate whether lncRNA-SNHG7 can enhance chemotherapy resistance and cell viability of BC cells by regulating miR-186.

Methods: SK-BR-3 and SNHG7 of HER2+BC cells were induced to enhance the resistance of BC cells to trastuzumab by regulating miR-186, and to regulate the expression levels of SNHG7 and miR-186. The sensitivity of drug-resistant cells to trastuzumab and the changes of cell proliferation, migration, apoptosis, and EMT were measured and verified by tumorigenesis in vivo. The effects of miR-186 on SNHG7 were investigated through rescue experiments; the regulatory relationship between the expression of SNHG7 and miR-186 was verified by the double luciferase reporter (DLR) and the mechanism of SNHG7 was explored.

Results: Down-regulation of SNHG7 or up-regulation of miR-186 could increase the sensitivity of BC cells to trastuzumab, inhibit the proliferation, migration and EMT, and promote apoptosis. Compared with the down-regulation of SNHG7 or miR-186 alone, simultaneous down-regulation of SNHG7 and miR-186 on drug-resistant cells brought notably lower sensitivity to trastuzumab and apoptosis rate, and higher proliferation and apoptosis ability. The DLR showed that miR-186 could specifically inhibit the expression of SNHG7. The results of tumorigenesis in vivo revealed that down-regulation of SNHG7 or up-regulation of miR-186 could improve the therapeutic effect of trastuzumab and reduce the tumor volume, and miR-186 could also antagonize the effect of SNHG7.

Conclusion: Down-regulation of SNHG7-targeted miR-186 can reverse trastuzumab resistance of BC cells, inhibit the proliferation, migration, and EMT levels of BC cells, and promote apoptosis.

Citing Articles

Harnessing the potential of long non-coding RNAs in breast cancer: from etiology to treatment resistance and clinical applications.

Wang Y, Bu N, Luan X, Song Q, Ma B, Hao W Front Oncol. 2024; 14:1337579.

PMID: 38505593 PMC: 10949897. DOI: 10.3389/fonc.2024.1337579.

Resistance of breast cancer cells to paclitaxel is associated with low expressions of miRNA-186 and miRNA-7.

Apollonova V, Plevako D, Garanin A, Sidina E, Zabegina L, Knyazeva M Cancer Drug Resist. 2023; 6(3):596-610.

PMID: 37842231 PMC: 10571055. DOI: 10.20517/cdr.2023.19.

The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer.

Arriaga-Canon C, Contreras-Espinosa L, Aguilar-Villanueva S, Bargallo-Rocha E, Garcia-Gordillo J, Cabrera-Galeana P Int J Mol Sci. 2023; 24(8).

PMID: 37108589 PMC: 10138835. DOI: 10.3390/ijms24087426.

MicroRNA-186 suppresses cell proliferation and metastasis in bladder cancer.

Liang J, Li P, Zhu Y, Zheng S, Liu J, Song S Afr Health Sci. 2023; 22(4):56-63.

PMID: 37092087 PMC: 10117455. DOI: 10.4314/ahs.v22i4.8.

Metformin and long non-coding RNAs in breast cancer.

Gholami M, Klashami Z, Ebrahimi P, Mahboobipour A, Farid A, Vahidi A J Transl Med. 2023; 21(1):155.

PMID: 36849958 PMC: 9969691. DOI: 10.1186/s12967-023-03909-x.

References

He M, Jin Q, Chen C, Liu Y, Ye X, Jiang Y . The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells. Oncogene. 2019; 38(28):5551-5565. DOI: 10.1038/s41388-019-0817-3. View

Liang H, Zhang X, Liu B, Jia G, Li W . Circular RNA circ-ABCB10 promotes breast cancer proliferation and progression through sponging miR-1271. Am J Cancer Res. 2017; 7(7):1566-1576. PMC: 5523036. View

Luo X, Song Y, Tang L, Sun D, Ji D . LncRNA SNHG7 promotes development of breast cancer by regulating microRNA-186. Eur Rev Med Pharmacol Sci. 2018; 22(22):7788-7797. DOI: 10.26355/eurrev_201811_16403. View

Chen K, Abuduwufuer A, Zhang H, Luo L, Suotesiyali M, Zou Y . SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway. Eur Rev Med Pharmacol Sci. 2019; 23(16):6935-6943. DOI: 10.26355/eurrev_201908_18733. View

Sun X, Huang T, Liu Z, Sun M, Luo S . LncRNA SNHG7 contributes to tumorigenesis and progression in breast cancer by interacting with miR-34a through EMT initiation and the Notch-1 pathway. Eur J Pharmacol. 2019; 856:172407. DOI: 10.1016/j.ejphar.2019.172407. View

Dong H, Hu J, Zou K, Ye M, Chen Y, Wu C . Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer. Mol Cancer. 2019; 18(1):3. PMC: 6323810. DOI: 10.1186/s12943-018-0931-9. View

Veneziano D, Marceca G, Di Bella S, Nigita G, Distefano R, Croce C . Investigating miRNA-lncRNA Interactions: Computational Tools and Resources. Methods Mol Biol. 2019; 1970:251-277. DOI: 10.1007/978-1-4939-9207-2_14. View

Dong H, Wang W, Chen R, Zhang Y, Zou K, Ye M . Exosome-mediated transfer of lncRNA‑SNHG14 promotes trastuzumab chemoresistance in breast cancer. Int J Oncol. 2018; 53(3):1013-1026. PMC: 6065402. DOI: 10.3892/ijo.2018.4467. View

Sun W, Zhang Y, Xue P . miR-186 inhibits proliferation, migration, and epithelial-mesenchymal transition in breast cancer cells by targeting Twist1. J Cell Biochem. 2018; 120(6):10001-10009. DOI: 10.1002/jcb.28283. View

10.

Palomeras S, Diaz-Lagares A, Vinas G, Setien F, Ferreira H, Oliveras G . Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer. Breast Cancer Res. 2019; 21(1):79. PMC: 6612099. DOI: 10.1186/s13058-019-1160-x. View

11.

Paraskevopoulou M, Hatzigeorgiou A . Analyzing MiRNA-LncRNA Interactions. Methods Mol Biol. 2016; 1402:271-286. DOI: 10.1007/978-1-4939-3378-5_21. View

12.

Han Y, Zhou S, Wang X, Mao E, Huang L . SNHG14 stimulates cell autophagy to facilitate cisplatin resistance of colorectal cancer by regulating miR-186/ATG14 axis. Biomed Pharmacother. 2019; 121:109580. DOI: 10.1016/j.biopha.2019.109580. View

13.

Zhang N, Cao C, Zhu Y, Liu P, Liu L, Lu K . Primary breast lymphoma: A single center study. Oncol Lett. 2017; 13(2):1014-1018. PMC: 5351386. DOI: 10.3892/ol.2016.5483. View

14.

Snow K, Judd W . Characterisation of adriamycin- and amsacrine-resistant human leukaemic T cell lines. Br J Cancer. 1991; 63(1):17-28. PMC: 1971666. DOI: 10.1038/bjc.1991.7. View

15.

Chen Z, Xu L, Shi W, Zeng F, Zhuo R, Hao X . Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990-2017. Breast Cancer Res Treat. 2020; 180(2):481-490. DOI: 10.1007/s10549-020-05561-1. View

16.

Muhammad N, Steele R, Isbell T, Philips N, Ray R . Bitter melon extract inhibits breast cancer growth in preclinical model by inducing autophagic cell death. Oncotarget. 2017; 8(39):66226-66236. PMC: 5630406. DOI: 10.18632/oncotarget.19887. View

17.

Burnett J, Korkaya H, Ouzounova M, Jiang H, Conley S, Newman B . Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options. Sci Rep. 2015; 5:15821. PMC: 4629137. DOI: 10.1038/srep15821. View

18.

Shi J, Li F, Yao X, Mou T, Xu Z, Han Z . The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition. Oncogene. 2018; 37(22):3022-3038. PMC: 5978807. DOI: 10.1038/s41388-018-0204-5. View

19.

Mohammad N, Singh S, Malvi P, Chaube B, Athavale D, Vanuopadath M . Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: Involvement of p53 and Fas receptor ligand complex. Sci Rep. 2015; 5:11853. PMC: 4493576. DOI: 10.1038/srep11853. View

20.

Mohammad N, Malvi P, Meena A, Singh S, Chaube B, Vannuruswamy G . Cholesterol depletion by methyl-β-cyclodextrin augments tamoxifen induced cell death by enhancing its uptake in melanoma. Mol Cancer. 2014; 13:204. PMC: 4175626. DOI: 10.1186/1476-4598-13-204. View